Cilimox

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cilimox

Property Description
Active ingredient Amoxicillin (as Amoxicillin trihydrate)
Form Oral capsules, Oral suspension (syrup)
Pharmacological class Beta-lactam antibiotic / Aminopenicillin
Common use Treating susceptible bacterial infections
Origin Semi-synthetic

What Type of Medicine is Cilimox?

Cilimox is a prescription-only medication whose active component is the widely used antibiotic, Amoxicillin. It is clinically recognized for its reliable efficacy as a broad-spectrum antibacterial agent against susceptible organisms. It is classified as an antibiotic and belongs to the beta-lactam family, specifically the aminopenicillin class. This classification places it within the established penicillin group, though its structure provides a broader effective spectrum than older penicillin compounds. The medicinal substance is considered semi-synthetic, meaning it is derived from the natural Penicillium fungus but has been chemically modified to improve its absorption and efficacy. As a single-agent product, Cilimox contains only the active antibacterial substance, Amoxicillin, without combining it with other therapeutic drugs.


Composition and General Purpose

The medication’s core component is the active ingredient Amoxicillin, frequently supplied as Amoxicillin trihydrate. Cilimox is designed for the oral route of administration and is typically available in two main dosage forms: oral capsules for adults and older children, and a powder for reconstitution that becomes a liquid suspension or syrup. This liquid form is often prepared to facilitate administration to pediatric patients. The general therapeutic purpose of Cilimox is to treat a variety of bacterial infections caused by susceptible organisms, such as those commonly encountered in respiratory or ear infections. Its mechanism of action is bactericidal, meaning it functions by actively destroying the bacteria that cause the infection rather than simply inhibiting their growth. This effective targeting and killing of susceptible bacteria is how the medicine helps resolve the underlying infection.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Cilimox?

Possible Side Effects and Safety Information

Cilimox, containing Amoxicillin, has an official safety profile organized by regulatory authorities based on the frequency and the body system affected. All adverse reactions are classified and documented in governmental regulatory labeling.

Frequency-Classified Adverse Reactions

The most frequently documented side effects are categorized as Common. These include diarrhea, nausea, vomiting, and skin rash. Effects categorized as Very Rare include severe reactions like leukopenia, hemolytic anemia, hepatitis, cholestatic jaundice, and nervous system effects such as convulsions and dizziness.

System-Organ-Class Safety Groups

Adverse events are formally grouped by the system-organ-class they impact. Effects are documented primarily in the Gastrointestinal system, the Immune System (hypersensitivity), Skin and Subcutaneous Tissue disorders, the Hepatobiliary system (liver function), and the Hemic and Lymphatic system.

Serious Adverse Reactions and Safety Constraints

Regulatory documents list several severe reactions. These include potentially fatal anaphylactic reactions and Severe Cutaneous Adverse Reactions (SCAR). Clostridioides difficile-associated diarrhea (CDAD) is also listed as a serious reaction, with symptoms that may appear during or even months after treatment. Cilimox is contraindicated in individuals with a known history of severe hypersensitivity to any penicillin or other beta-lactam agent.

Specific safety considerations exist for certain groups. The label notes that the risk of toxic reactions may be greater in elderly patients or those with impaired renal function. The development of an erythematous rash is associated with use in patients with infectious mononucleosis.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Cilimox (Amoxicillin) is primarily defined by the risks associated with high drug concentrations and compromised elimination. The official regulatory profile documents potential effects on the renal/urinary system and the central nervous system.

Documented Manifestations and Risks

Documented manifestations include the development of crystalluria and subsequent complications such as oliguric renal failure or interstitial nephritis. Convulsions (seizures) are a reported risk, especially in patients with impaired renal function due to a greater toxicity risk. This risk is specifically documented in both adult and pediatric patients.

Immediate Emergency Actions

Regulatory guidance mandates that individuals seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if severe signs, such as collapse, seizure, trouble breathing, or inability to be awakened, are present.

Management focuses on symptomatic and supportive treatment. Maintaining adequate fluid intake and diuresis is required to mitigate the risk of crystalluria, and hemodialysis is documented as a procedure that can remove the drug in severe cases. The associated renal impairment is typically reversible upon cessation of the medication.

Therapeutic Uses of Cilimox

Cilimox is an anti-infective agent that is commonly applied across multiple therapeutic domains for managing symptoms associated with acute bacterial infections, which contributes to improving comfort during the symptomatic period. This is commonly applied in scenarios where additional management of discomfort is required, which may help ease the overall symptom burden. Amoxicillin is relevant for managing bacterial infections of the ears, nose, throat, respiratory tract, skin, and urinary tract.


Easing Acute Discomfort from Ear, Throat, and Sinus Infections

This domain covers infections that involve inflammatory or irritative states, such as acute bacterial sinusitis, tonsillitis, and otitis media. Cilimox is applied to ease symptoms related to physical discomfort, including pain and swelling, and contributes to improved comfort related to swallowing, breathing, and hearing.


Addressing Symptoms of Respiratory and Systemic Illness

The medication is commonly applied in clinical settings that involve acute or disruptive symptom patterns from bacterial lower respiratory infections like acute bronchitis and pneumonia. It provides support that helps ease the overall symptom burden of symptoms related to systemic imbalance, including persistent cough, high fever, and generalized fatigue, and supports the patient during difficult episodes by easing distress.


Quick Fact: Application in Localized Discomfort

Cilimox may assist with managing symptoms related to physical discomfort arising from bacterial infections in the ears, throat, and teeth, offering symptomatic relief that helps maintain a sense of stability when symptoms are more noticeable.


Summary of Therapeutic Use

Cilimox is commonly used to help manage acute conditions presenting with significant symptomatic burden in the following areas: respiratory tract infections, ear/nose/throat infections, skin and soft-tissue infections, and urinary tract infections. The primary benefit is in easing the overall symptom burden associated with systemic imbalance (fever, malaise) and localized inflammation (pain, swelling).

Regulatory References

  1. Amoxicillin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Cilimox? — Official Regulatory Information

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and pediatric patients ge 3 months of age with normal or mild-to-moderate renal function.
Populations for whom use is not recommended Individuals with Infectious Mononucleosis (Glandular Fever).
Populations for whom use is contraindicated Patients with a history of severe immediate hypersensitivity to Amoxicillin or any other beta-lactam agent (penicillins, cephalosporins).
Age-related eligibility rules Use is established for individuals aged 3 months and older. Infants le 3 months are eligible but restricted to a defined lower maximum dose.
Condition-specific eligibility rules Severe Renal Impairment (GFR <30 mL/min) requires the total daily dose to be significantly reduced; the highest-strength dose is generally not recommended.
Pregnancy and lactation eligibility status Pregnancy Category B (FDA). Use during pregnancy and breastfeeding is generally permitted following a professional assessment.

Official Eligibility Statements

  • The medicine is contraindicated for any individual with a history of a severe immediate allergic reaction to Amoxicillin or any other penicillin or cephalosporin antibiotic.
  • The medicine should not be administered to patients with Infectious Mononucleosis (Glandular Fever).
  • Severe renal impairment requires the total daily dose to be reduced.
  • Use is established for pediatric patients aged 3 months and older, and generally permitted for adults.

Connection to the overall eligibility profile: Official regulatory documents define eligibility for this medicine primarily by absolute prohibition based on prior severe allergic reactions to penicillin-class drugs, and by formal exclusion for patients with infectious mononucleosis. For all other approved populations, eligibility is conditional, with mandatory dose limitations for infants le 3 months and adults with severe kidney impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cilimox, which contains the active ingredient Amoxicillin, may interact with several other medications, primarily by affecting how the other drug is cleared from the body or by increasing the risk of certain side effects. Patients should ensure their healthcare provider is aware of all current medications, including over-the-counter products and supplements.

Interacting Product Category Interaction Summary and Risk Profile
Methotrexate Co-administration may lead to increased plasma concentrations of methotrexate. This effect is due to competition for the common renal tubular secretion system, which reduces the elimination of methotrexate. The heightened levels raise the risk of serious toxicity, including haematological (blood cell) and gastrointestinal side effects. The risk is more pronounced in elderly patients and those with pre-existing kidney impairment. Close monitoring is essential.
Oral Anticoagulants (e.g., Warfarin) Amoxicillin use may cause an alteration in gut flora, potentially affecting Vitamin K metabolism and leading to an increased risk of bleeding. More frequent monitoring of International Normalized Ratio (INR) is recommended in patients receiving this combination, especially in those with liver or kidney dysfunction.
Allopurinol / Probenecid Concurrent use of Allopurinol with Amoxicillin is associated with a significantly increased incidence of skin rash or hives. Probenecid can delay Amoxicillin's renal excretion, leading to higher and prolonged Amoxicillin blood levels.

Note on Hormonal Contraceptives: While widely discussed, current regulatory consensus does not definitively support a need for extra contraceptive precautions with Amoxicillin; however, the potential for reduced efficacy remains a theoretical concern. Consult the official prescribing information for the specific contraceptive product being used.

Mechanism of Action

Irreversible Blockade of Bacterial Cell Wall Enzymes

Cilimox, containing Amoxicillin, exerts its primary action through the irreversible inhibition of essential bacterial enzymes called Penicillin-Binding Proteins (PBPs). The drug acts as a structural analog, forming a stable, covalent bond with a critical active site on the PBP enzyme. PBPs are crucial for synthesizing and cross-linking the structural polymer peptidoglycan, which provides the rigidity of the bacterial cell wall. This definitive enzyme blockade results in a functional failure of the pathogen to maintain its structural integrity.

Initiation of the Bactericidal Lysis Cascade

The inhibition of PBPs triggers a subsequent cascade where molecular action translates into the physiological effect of bacterial death. By preventing the formation of a robust cell wall, Amoxicillin exposes the bacterium to its own high internal osmotic pressure. This structural defect, combined with the activation of internal autolytic enzymes, results in the rapid rupture and destruction (lysis) of the susceptible bacterial cell. This entire process is categorized as bactericidal, a process that results in the active elimination of the target organism.

Constraints of Mechanistic Specificity

The drug's inhibitory activity is prevented by bacteria that produce beta-lactamase enzymes, which hydrolyze and inactivate the drug before it can reach the PBPs. Furthermore, the bactericidal effect is reliant on active cell wall synthesis; consequently, bacteria that are not actively dividing (non-proliferating) exhibit reduced susceptibility to this mechanism.

Dosage and Administration Information

How to Use Cilimox: Official Administration Guidelines

Cilimox (Amoxicillin) is administered according to specific instructions which govern the route, frequency, and duration of use. This information is not a substitute for individual medical instruction.


Administration and Dosage Structure

The primary route of administration for Cilimox capsules and suspension is oral. The medicine is typically scheduled for Twice Daily (q12h) or Three Times Daily (q8h) dosing.

Standard Adult Dosing generally ranges from 250 mg to 875 mg per dose, with the specific amount determined by the patient's condition. The medicine can be taken with or without food as absorption is not significantly affected by meals.


Preparation and Procedural Rules

For the oral suspension, the powder must first be reconstituted with water as specified in the instructions and shaken well before each use. Capsules must be swallowed whole. The full prescribed course duration must be completed, even if the patient feels better, often requiring a minimum of 10 days for certain infections to prevent complications.


Population-Specific Use

Pediatric dosing for children under 40 kg is calculated based on body weight (mg/kg/day) and divided into two or three daily administrations. Dose adjustments are mandatory for patients with severe renal impairment (Creatinine Clearance < 30 mL/min), and the 875 mg twice-daily dose is not recommended in this group.

Recent Clinical Evidence

Research evidence / Overview of studies

Key Findings on the Combination of Compounds

Studies have explored whether the combination of compounds demonstrates a change in the frequency or severity of symptoms in participants. Research has investigated the measurement of the compound within the body, including rate of uptake and the relationship between amount administered and measured blood concentration.

  • One meta-analysis evaluated the association between the compound and various results compared to control groups.
  • The findings on tolerability and results of the drug evaluation have been reported across diverse adult populations in various clinical trials.

Symptom Management and Onset

Early-stage laboratory studies have investigated how the compound interacts with the body, focusing on specific molecular characteristics. Clinical studies have examined factors associated with the observed rate of symptom return.

Specifically, some research has investigated the time to change in acute symptoms, as well as the impact on the ability of participants to perform daily tasks. The timing of administration relative to symptom onset and potential associations with outcomes has been a subject of research.

Long-Term Research and Safety

Evidence remains limited regarding the effects of long-term use (defined as more than two years) on major organ systems. Further studies are ongoing to examine long-term safety and potential associations with rare adverse events. Studies included the assessment of adverse findings during the research period.

Frequently Asked Questions (FAQ)

Common questions about Cilimox (FAQ)


Q: How quickly should Cilimox start working?

Official product information indicates that the active ingredient, Amoxicillin, reaches its highest concentration in the bloodstream within 1 to 2 hours after administration. Based on clinical studies, patients generally notice an improvement in their symptoms during the first few days of treatment.


Q: Why is Cilimox used for more than one condition?

Cilimox contains Amoxicillin, which is classified as a broad-spectrum antibiotic. This indicates that its mechanism of action is effective against a wide variety of different susceptible bacterial organisms, allowing it to be used for multiple types of infections caused by those bacteria.


Q: Does Cilimox cause drowsiness?

Drowsiness itself is not typically listed as a common side effect in official documents. However, related nervous system effects like dizziness and agitation are documented as adverse reactions. Dizziness and trouble sleeping are documented nervous system effects that patients may experience.


Q: Is Cilimox the same as [Name of similar common drug]?

Cilimox is a brand name for a specific product. Its active ingredient is the generic drug, Amoxicillin. While Amoxicillin belongs to the larger penicillin class of antibiotics, it is a distinct chemical compound from other named drugs within that class.


Q: What are the warning signs of a serious reaction to Cilimox?

Serious reactions documented in official prescribing information include potentially severe skin conditions and anaphylaxis. Warning signs may include difficulty breathing or swallowing, swelling of the face or throat, severe blistering or peeling skin (rash), or severe, watery diarrhea (CDAD) that occurs during or after treatment.


Q: What is the maximum duration of treatment with Cilimox mentioned in official documents?

The required length of treatment is specific to the infection being addressed, with most courses lasting between 7 and 14 days. Official labeling notes that therapy may be required for several weeks in some complex or serious infections. The precise duration is established by a healthcare provider based on the condition.


Q: Can Cilimox be crushed or split if I have trouble swallowing pills?

Official product labeling specifies that certain forms, such as extended-release tablets, must not be crushed. For individuals who may have difficulty swallowing solid forms, the liquid oral suspension of Cilimox is available as an alternative formulation.


Q: Are there different strengths or formulations of Cilimox?

Yes, Cilimox is supplied in multiple formulations, including oral capsules, tablets (which may be chewable), and powder for oral suspension (liquid). Common dose strengths range from 250 mg to 875 mg per dose, as noted in the regulatory documents.


Q: Is there a list of all known interactions with Cilimox?

Yes. Regulatory documents such as the FDA's Full Prescribing Information contain a dedicated, comprehensive section listing all known and potentially significant drug-to-drug interactions. This list details how Cilimox may affect or be affected by other medications.


Q: How is Cilimox processed by the body?

According to pharmacokinetics data, the medicine is rapidly absorbed into the bloodstream after administration and is partially metabolized in the liver. Most of the drug is then eliminated unchanged via the kidneys in the urine, typically with a short elimination half-life.


Q: Is the name Cilimox a brand name or a generic name?

Cilimox is a specific brand name medication. The active antibacterial component is the generic drug, Amoxicillin, which is the substance responsible for the therapeutic effect.


Q: How is the safety of Cilimox monitored after it is approved?

Regulatory agencies continue to oversee the medication’s safety through a system called post-marketing surveillance. This process involves actively collecting and assessing reports of adverse reactions that occur after the product is made available to the public to ensure its known benefit-risk profile remains favorable.


Q: Can Cilimox be used long-term?

Cilimox is typically prescribed for short-term use to treat acute infections, with most courses lasting between 7 and 14 days. While use for several weeks may be required for serious infections, research evidence regarding the effects of long-term use (over two years) is limited.


Q: Is Cilimox approved in countries outside the US?

Yes, the active ingredient, Amoxicillin, is listed on the World Health Organization (WHO) Model List of Essential Medicines. This confirms that it is officially recognized, approved, and considered a core medication necessary for healthcare systems globally.


Q: What happens if a dose of Cilimox is missed?

Official patient instructions indicate that a missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is usually skipped, and the regular schedule is continued. Official information advises against taking double doses.


Q: Can I drink coffee while taking Cilimox?

Official regulatory labels do not list a specific contraindication or known drug-to-caffeine interaction. General patient guidance often addresses limiting consumption of caffeine or choosing low-caffeine options, noting the potential to worsen stomach irritation, which is a common side effect of the medicine.


Q: How long does Cilimox stay in your system after stopping it?

Cilimox (Amoxicillin) has a short elimination half-life of about one hour. The medication is rapidly cleared from the bloodstream, with the majority of the drug being eliminated by the kidneys in the urine within 6 to 8 hours of the final dose.


Q: Can Cilimox affect blood sugar levels?

Cilimox is not documented in official prescribing information to change a patient's actual blood sugar levels. However, it is noted that high concentrations in the urine may lead to false-positive reactions when testing for glucose in the urine using certain non-enzymatic methods.


Q: Does Cilimox have a bitter taste?

The liquid oral suspension formulation is generally designed to be palatable for easier use. However, if the tablets or capsules are broken, crushed, or dispersed in water, the taste can be described as bitter.


Q: Can Cilimox affect the results of lab tests?

Yes, official labeling confirms that the medicine can interfere with specific diagnostic tests. It may cause false-positive results when testing for glucose in the urine using certain traditional test methods. It may also transiently decrease the plasma concentration of certain hormones in pregnant women.


Q: Can I take pain relievers like ibuprofen with Cilimox?

Based on regulatory data summarized in clinical drug interaction databases, a direct chemical interaction between Cilimox (Amoxicillin) and the common pain reliever ibuprofen is not listed.


Q: Is Cilimox known to interact with alcohol?

Official warnings state that Amoxicillin does not have a direct chemical interaction with alcohol. However, consuming alcohol may worsen common side effects, such as nausea and diarrhea, and alcohol consumption itself may impede recovery from infection.


Q: Does Cilimox cause changes in mood or behavior?

In rare instances, central nervous system effects are reported as adverse reactions in regulatory documents. These have included reports of anxiety, agitation, confusion, and other behavioral changes.


Q: Is a metallic taste a common side effect of Cilimox?

Yes, a change in the sense of taste, known medically as dysgeusia or abnormal taste sense, is a documented side effect of Amoxicillin. This taste change is sometimes perceived by patients as a metallic taste in the mouth.

How should Cilimox be stored and disposed of?

Storage Requirements

Formulation Required Storage Condition
Capsules/Tablets/Powder Store at Controlled Room Temperature (20 C to 25 C) and below 25 C in a cool, dry place.
Reconstituted Suspension Must be refrigerated (2 C to 8 C).

The medicine must be kept in its original, tightly closed container and protected from direct sunlight, moisture, and heat. The powder and solid forms must not be frozen. The liquid suspension is stable for only 14 days when refrigerated and any unused portion must be discarded after this period.

Child-Safety and Disposal

Cilimox must be stored out of the sight and reach of children and pets in a secure location. For disposal, unused or expired medicine must be discarded properly; it is strictly prohibited to flush it down the toilet or throw it into the drain. The preferred method is using an authorized drug take-back program or securely mixing it with an unappealing substance for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cilimox found in:

A-Z Index: